Premium
YKL‐40 and MMP‐9 as serum markers for patients with primary central nervous system lymphoma
Author(s) -
Hottinger Andreas F.,
Iwamoto Fabio M.,
Karimi Sasan,
Riedel Elyn,
Dantis Jocelynn,
Park Joseph,
Panageas Katherine S.,
Lassman Andrew B.,
Abrey Lauren E.,
Fleisher Martin,
Holland Eric C.,
DeAngelis Lisa M.,
Hormigo Adília
Publication year - 2011
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.22360
Subject(s) - primary central nervous system lymphoma , medicine , magnetic resonance imaging , hazard ratio , gastroenterology , lymphoma , central nervous system , prospective cohort study , pathology , radiology , confidence interval
Objective: To evaluate YKL‐40 and MMP‐9 proteins as tumor biomarkers in serum samples from patients with primary central nervous system lymphoma (PCNSL). Methods: In this prospective longitudinal study, serum samples from consecutive patients with histologically confirmed PCNSL were collected concurrently with magnetic resonance imaging (MRI) scans at multiple time points and were analyzed for levels of YKL‐40 and MMP‐9 by enzyme‐linked immunosorbent assay. Marker levels were correlated to disease status and survival. Results: Forty‐five patients with PCNSL were accrued. Median follow‐up for survivors was 25 months, and 21 (47%) died during the study. A total of 230 serum samples were collected, and 93% had corresponding MRI scans. PCNSL patients without evidence of radiographic disease (29 patients, 131 samples) had significantly lower levels of serum YKL‐40 and MMP‐9 than patients with active tumor (n = 34 patients, 84 samples; p = 0.03 and 0.01, respectively). There was a significant inverse correlation between survival and doubling of the YKL‐40 level (hazard ratio, 1.7; p = 0.01). Interpretation: In patients with PCNSL, serum levels of YKL‐40 and MMP‐9 are associated with radiographic disease status. Longitudinal increase in serum levels of YKL‐40, but not MMP‐9, predicts survival in patients with PCNSL. ANN NEUROL 2011